StreetInsider.com News Articles

Form 4 BioNTech SE For: Oct 08 Filed by: Sahin Ugur

Fri, 09 Oct 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20261009/27172058.html

Argus Starts BioNTech (BNTX) at Hold

Thu, 08 Oct 2026 08:40:13 -0400

Argus initiates coverage on BioNTech (NASDAQ: BNTX) with a Hold rating.

For an analyst ratings summary and ratings history on BioNTech click here. For more ratings news on BioNTech click here.

Shares of BioNTech closed at $95.25 yesterday.

Form 4 BioNTech SE For: Oct 07 Filed by: Sahin Ugur

Wed, 07 Oct 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20261007/27161980.html

BioNTech (BNTX) PT Lowered to $114 at Morgan Stanley

Wed, 07 Oct 2026 07:58:14 -0400

Morgan Stanley analyst Terence Flynn lowered the price target on BioNTech (NASDAQ: BNTX) to $114.00 (from $115.00) while maintaining a Overweight rating.

Novavax and Moderna shares fall after plague concerns ease, Citi comments

Wed, 07 Oct 2026 05:06:51 -0400

Investing.com -- Novavax Inc and Moderna Inc shares declined on Wednesday after rising sharply the previous day on reports of a suspected pneumonic plague case in Russia.

Novavax (NASDAQ:NVAX) fell 11% during trading after gaining 20% on Tuesday. Moderna shares dropped 6% following a 7% increase the day before. The iShares Biotechnology ETF declined 3%, while the S&P 500 rose 1%.

The World Health Organization currently assesses the broader public health risk as low. The plague remains unconfirmed and contacts have tested negative, according to Citi.

BioNTech SE (NASDAQ:BNTX) showed limited movement, rising 1% on Tuesday before trading flat on Wednesday. Citi noted

Novavax and Moderna shares fall after plague concerns ease, Citi comments

Wed, 07 Oct 2026 05:06:51 -0400

Investing.com -- Novavax Inc and Moderna Inc shares declined on Wednesday after rising sharply the previous day on reports of a suspected pneumonic plague case in Russia.

The World Health Organization currently assesses the broader public health risk as low. The plague remains unconfirmed and contacts have tested negative, according to Citi.

BioNTech SE (NASDAQ:BNTX) showed limited movement, rising 1% on Tuesday before trading flat on Wednesday. Citi noted

Novavax and Moderna shares fall after plague concerns ease, Citi comments

Wed, 07 Oct 2026 05:06:51 -0400

Investing.com -- Novavax Inc and Moderna Inc shares declined on Wednesday after rising sharply the previous day on reports of a suspected pneumonic plague case in Russia.

The World Health Organization currently assesses the broader public health risk as low. The plague remains unconfirmed and contacts have tested negative, according to Citi.

BioNTech SE (NASDAQ:BNTX) showed limited movement, rising 1% on Tuesday before trading flat on Wednesday. Citi noted

Form 4 BioNTech SE For: Oct 05 Filed by: Sahin Ugur

Tue, 06 Oct 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20261006/27156220.html

Form 4 BioNTech SE For: Oct 01 Filed by: Sahin Ugur

Fri, 02 Oct 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20261002/27142723.html

Form 4 BioNTech SE For: Sep 29 Filed by: Sahin Ugur

Wed, 30 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260930/27129017.html

Form 4 BioNTech SE For: Sep 25 Filed by: Sahin Ugur

Mon, 28 Sep 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260928/27115509.html

BioNTech to close Germany and Singapore sites after sale fails

Mon, 28 Sep 2026 09:07:00 -0400

Investing.com -- BioNTech said Monday it will shut down manufacturing facilities in Germany and Singapore after failing to secure buyers for the sites as the company shifts away from pandemic-era production.

The German vaccine maker stated that a comprehensive sales process did not result in completed transactions for the locations.

"Despite the best efforts of all those involved and a wide-ranging sales process, it has unfortunately not been possible to finalise a sale," a company spokesperson said.

BioNTech announced in May its plans to find purchasers for its German facilities in Idar-Oberstein, Marburg and Tuebingen, along with its Singapore location, or proceed with

Form 4 BioNTech SE For: Sep 23 Filed by: Sahin Ugur

Thu, 24 Sep 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260924/27102512.html

Form 4 BioNTech SE For: Sep 21 Filed by: Sahin Ugur

Tue, 22 Sep 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260922/27091761.html

Form 4 BioNTech SE For: Sep 17 Filed by: Sahin Ugur

Fri, 18 Sep 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260918/27081048.html

Form 6-K BioNTech SE For: Sep 18

Fri, 18 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260918/27080630.html

Form 4 BioNTech SE For: Sep 15 Filed by: Sahin Ugur

Wed, 16 Sep 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260916/27070887.html

UBS Reiterates Buy Rating on BioNTech (BNTX) Following Lung Cancer Updates

Wed, 16 Sep 2026 08:40:39 -0400

UBS analyst David Dai reiterated a Buy rating and $135.00 price target on BioNTech (NASDAQ: BNTX).

The analyst commented, "BNTX presented two important lung cancer updates at WCLC 2026 -- 1) first ever PD-L1xVEGF + B7-H3 ADC combo (pumi+Elfe-D) in 1L ES-SCLC, and 2) gotistobart (anti-CTLA) OS data in 2L+ NSCLC. Pumi+Elf-D exceeded our expectations with potentially best-in-class efficacy and clean safety in 1L ES SCLC, supporting advancement into Phase 3 trial. Combining a PD-L1×VEGF bispecific with an ADC showed 70% ORR overall and 92% ORR in 1L, exceeding that of pumi+chemo combo and other B7-H3 ADCs. Safety looked clean with no DLT and low discontinuation rate (3.9%). Moreover,

BioNTech (BNTX) PT Raised to $140 at Berenberg

Wed, 16 Sep 2026 04:57:55 -0400

Berenberg analyst Harry Gillis raised the price target on BioNTech (NASDAQ: BNTX) to $140.00 (from $132.00) while maintaining a Buy rating.

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat